Home  >  Companies  >  Capsule Pharmacy
Capsule Pharmacy
Digital pharmacy offering same-day prescription delivery and in-app medication management

Funding

$570.00M

2021

Details
Headquarters
New York, NY
CEO
Champ Bennett
Website
Milestones
FOUNDING YEAR
2016
Listed In
Overview
Filings

Funding Rounds

Share Name Issue Price Issued At
Series E $2.93 Feb 2023
Share Name Issue Price Issued At
Series 1-D $2.93 Apr 2021
Series 1-C $2.93 Sep 2019
Series 1-B $2.87 Aug 2018
Series 1-A $1.77 May 2017
View the source Certificate of Incorporation copy.

News

February 24, 2021

Ginger Partners with Capsule Pharmacy to Provide Same-Day Mental Health Medication Delivery

The partnership between Ginger and Capsule Pharmacy aims to improve access to mental health medications by offering same-day delivery, addressing care gaps in psychiatry and supporting patients in need of mental health interventions. This collaboration will provide professional supervision over medication plans and help ensure the safety and efficacy of members' medication regimens.
April 21, 2020

Capsule Pharmacy Expands Operations to Westchester County in Response to Increased Demand During Pandemic

Capsule's expansion into Westchester County is a strategic move to meet the rising demand for pharmaceutical deliveries during the pandemic, as the company has experienced a significant increase in orders since March. With its contact-free deliveries and new sanitation practices, Capsule aims to ensure the safety of its employees and customers while providing convenient access to medications.
September 16, 2019

Capsule Pharmacy Raises $200 Million to Expand Prescription Drug Delivery Service

Capsule's recent funding of $200 million will enable the online pharmacy startup to expand its prescription drug delivery service beyond New York City, allowing them to reach major markets nationwide.

DISCLAIMERS

This report is for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal trade recommendation to you.

This research report has been prepared solely by Sacra and should not be considered a product of any person or entity that makes such report available, if any.

Information and opinions presented in the sections of the report were obtained or derived from sources Sacra believes are reliable, but Sacra makes no representation as to their accuracy or completeness. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a determination at its original date of publication by Sacra and are subject to change without notice.

Sacra accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to Sacra. Sacra may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect different assumptions, views and analytical methods of the analysts who prepared them and Sacra is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

All rights reserved. All material presented in this report, unless specifically indicated otherwise is under copyright to Sacra. Sacra reserves any and all intellectual property rights in the report. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of Sacra. Any modification, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, or selling any report is strictly prohibited. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Sacra. Any unauthorized duplication, redistribution or disclosure of this report will result in prosecution.